THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS

Muthiah Vaduganathan,Robert A. Harrington,Gregg W. Stone,Philippe Gabriel Steg,C. Michael Gibson,Christian W. Hamm,Matthew J. Price,Alberto Menozzi,Jayne Prats,Efthymios Deliargyris,Kenneth W. Mahaffey,Harvey D. White,Deepak L. Bhatt

THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS

2016

Muthiah Vaduganathan
Robert A. Harrington
Gregg W. Stone
Philippe Gabriel Steg
C. Michael Gibson
Christian W. Hamm
Matthew J. Price
Alberto Menozzi
Jayne Prats
Efthymios Deliargyris
Kenneth W. Mahaffey
Harvey D. White
Deepak L. Bhatt

Cangrelor, an intravenous, reversible P2Y12 antagonist, was recently approved for use in patients undergoing percutaneous coronary intervention (PCI) in the US. We evaluated the efficacy and safety of cangrelor compared with clopidogrel in the subgroup who received glycoprotein IIb/IIIa inhibitors

Keywords:

Percutaneous coronary intervention
Cangrelor
Clopidogrel
Glycoprotein IIb/IIIa inhibitors
P2Y12
Cardiology
Internal medicine
Medicine
Conventional PCI
Antagonist
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations